A valuable diagnostic tool and therapeutic alternative for standard prostate cancer therapy has recently been proposed as a combination of a radioisotope and an antagonist that targets prostate-specific membrane antigen (PSMA) [71]. Here, FOLH1 is linked to prostate cancer.